Autologous Cell Therapy Market Trends and Forecast
The future of the global autologous cell therapy market looks promising with opportunities in the hospitals & clinic, ambulatory center, and academics & research markets. The global autologous cell therapy market is expected to grow with a CAGR of 22.4% from 2024 to 2030. The major drivers for this market are rising prevalence of chronic diseases, such as cardiovascular disorders, neurodegenerative diseases, and orthopedic conditions, continuous advancements in biotechnology, stem cell research, and cell isolation techniques, and growing shift towards personalized medicine approaches.
• Lucintel forecasts that bone marrow will remain the largest segment over the forecast period.
• Within this market, academics & research will remain the largest segment.
• North America will remain the largest region over the forecast period.
Country Wise Outlook for the Autologous Cell Therapy Market
• United States: Gilead Sciences announced a collaboration with academic institutions to advance research in autologous cell therapies for cancer treatment, supported by government grants promoting biomedical innovation.
• Germany: Miltenyi Biotec expanded its production capacity for cell isolation and processing systems, aiming to meet growing demand for autologous cell therapies in Europe. Government funding supports biotechnology advancements.
• Japan: Healios K.K. received regulatory approval for its autologous cell therapy for treating age-related macular degeneration (AMD), marking a milestone in JapanÄX%$%Xs healthcare innovation initiatives.
• China: Cellular Biomedicine Group launched a clinical trial for autologous cell therapy in regenerative medicine, supported by government initiatives to advance biotechnological research and development.
• India: Stempeutics Research partnered with hospitals to initiate clinical trials for autologous cell therapies targeting orthopedic conditions, supported by government policies promoting biotech industry growth and healthcare innovation.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Autologous Cell Therapy Market by Segment
The study includes a forecast for the global autologous cell therapy market by source, application, end use, and region.
Autologous Cell Therapy Market by Source [Value from 2018 to 2030]:
• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Haematopoietic Stem Cells
• Chondrocytes
• Others
Autologous Cell Therapy Market by Application [Value from 2018 to 2030]:
• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Others
Autologous Cell Therapy Market by End Use [Value from 2018 to 2030]:
• Hospitals & Clinics
• Ambulatory Centers
• Academics & Research
• Others
Autologous Cell Therapy Market by Region [Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Autologous Cell Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies autologous cell therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the autologous cell therapy companies profiled in this report include-
• BrainStorm Cell Therapeutics
• Pharmicell
• Opexa Therapeutics
• Caladrius Biosciences
• Lonza
• Bristol Myers Squibb
• Novartis
• Autolus therapeutics
• Tego Science
• Corning Incorporated
Recent Development in the Autologous Cell Therapy Market
• Gilead Sciences: Collaboration for Cancer Therapies Gilead Sciences partnered with academic institutions to advance research in autologous cell therapies for cancer treatment. The collaboration focuses on developing personalized cellular therapies to target hematologic malignancies and solid tumors, leveraging GileadÄX%$%Xs expertise in biotechnology and oncology.
• Miltenyi Biotec: Expansion of Production Capacity Miltenyi Biotec expanded its production capacity for cell isolation and processing systems, enhancing capabilities to support the growing demand for autologous cell therapies worldwide. The initiative aims to streamline cell therapy manufacturing processes and improve scalability to meet clinical and commercial needs.
• Healios K.K.: Regulatory Approval for AMD Treatment Healios K.K. received regulatory approval in Japan for its autologous cell therapy aimed at treating age-related macular degeneration (AMD). The approval marks a significant milestone in HealiosÄX%$%X efforts to provide innovative regenerative medicine solutions for ophthalmic disorders.
• Cellular Biomedicine Group: Clinical Trial Initiation Cellular Biomedicine Group initiated a clinical trial for autologous cell therapy in regenerative medicine applications. The trial focuses on evaluating the safety and efficacy of personalized cell therapies for treating degenerative diseases, supported by advancements in biotechnological research and development.
• Stempeutics Research: Clinical Trials for Orthopedic Conditions Stempeutics Research commenced clinical trials for autologous cell therapies targeting orthopedic conditions. The trials aim to assess the therapeutic potential of mesenchymal stem cells derived from patientsÄX%$%X own tissues, addressing musculoskeletal disorders through innovative regenerative approaches.
Features of the Global Autologous Cell Therapy Market
Market Size Estimates: Autologous cell therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Autologous cell therapy market size by source, application, end use, and region in terms of value ($B).
Regional Analysis: Autologous cell therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different sources, applications, end uses, and regions for the autologous cell therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the autologous cell therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for autologous cell therapy market?
Answer: The global autologous cell therapy market is expected to grow with a CAGR of 22.4% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the autologous cell therapy market?
Answer: The major drivers for this market are rising prevalence of chronic diseases, such as cardiovascular disorders, neurodegenerative diseases, and orthopedic conditions, continuous advancements in biotechnology, stem cell research, and cell isolation techniques, and growing shift towards personalized medicine approaches.
Q3. What are the major segments for autologous cell therapy market?
Answer: The future of the autologous cell therapy market looks promising with opportunities in the hospitals & clinic, ambulatory center, and academics & research markets.
Q4. Who are the key autologous cell therapy market companies?
Answer: Some of the key autologous cell therapy companies are as follows:
• BrainStorm Cell Therapeutics
• Pharmicell
• Opexa Therapeutics
• Caladrius Biosciences
• Lonza
• Bristol Myers Squibb
• Novartis
• Autolus therapeutics
• Tego Science
• Corning Incorporated
Q5. Which autologous cell therapy market segment will be the largest in future?
Answer: Lucintel forecasts that bone marrow will remain the largest segment over the forecast period.
Q6. In autologous cell therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the autologous cell therapy market by source (bone marrow, epidermis, mesenchymal stem cells, haematopoietic stem cells, chondrocytes, and others), application (cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and others), end use (hospitals & clinics, ambulatory centers, academics & research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Autologous Cell Therapy Market Market, Autologous Cell Therapy Market Market Size, Autologous Cell Therapy Market Market Growth, Autologous Cell Therapy Market Market Analysis, Autologous Cell Therapy Market Market Report, Autologous Cell Therapy Market Market Share, Autologous Cell Therapy Market Market Trends, Autologous Cell Therapy Market Market Forecast, Autologous Cell Therapy Market Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.